Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma.

Min Yuen Teo,Neha Ratna,Ashley Marie Regazzi,Danielle Elise Zimmerman,Deaglan Joseph McHugh,Andrew Leonard Laccetti,Han Xiao,Chung-Han Lee,David H. Aggen,Samuel Aaron Funt,Dean F. Bajorin,Gopa Iyer,Jonathan E. Rosenberg

Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma.

2021

Min Yuen Teo
Neha Ratna
Ashley Marie Regazzi
Danielle Elise Zimmerman
Deaglan Joseph McHugh
Andrew Leonard Laccetti
Han Xiao
Chung-Han Lee
David H. Aggen
Samuel Aaron Funt
Dean F. Bajorin
Gopa Iyer
Jonathan E. Rosenberg

458Background: Enfortumab vedotin (EV) and, for those with FGFR3 mutations (FGFR3+), erdafitinib, are established therapeutic options for refractory advanced urothelial carcinoma. However, optimal ...

Keywords:

Cancer research
Refractory
Medicine
Enfortumab vedotin
urothelial carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations